Wasatch Advisors LP Has $11.29 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Wasatch Advisors LP lessened its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 15.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 599,401 shares of the company’s stock after selling 108,976 shares during the quarter. Wasatch Advisors LP owned 0.79% of Nurix Therapeutics worth $11,293,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. US Bancorp DE lifted its position in Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after buying an additional 842 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock worth $138,000 after acquiring an additional 877 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Nurix Therapeutics during the fourth quarter valued at approximately $207,000. KLP Kapitalforvaltning AS bought a new position in Nurix Therapeutics in the fourth quarter valued at approximately $209,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Nurix Therapeutics during the 4th quarter worth approximately $266,000.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,825 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the sale, the chief financial officer now owns 33,724 shares in the company, valued at $488,660.76. This represents a 14.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,326 shares of company stock valued at $213,449. Corporate insiders own 7.20% of the company’s stock.

Analyst Upgrades and Downgrades

NRIX has been the subject of several recent analyst reports. Stephens reissued an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. Royal Bank of Canada lifted their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. dropped their target price on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Stifel Nicolaus reduced their price target on Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, April 9th. Finally, Leerink Partnrs upgraded Nurix Therapeutics to a “hold” rating in a research note on Monday, March 17th. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $30.44.

Nurix Therapeutics Stock Down 0.2 %

NRIX stock opened at $9.80 on Thursday. The company’s fifty day simple moving average is $13.48 and its 200 day simple moving average is $18.94. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56. The firm has a market cap of $747.11 million, a price-to-earnings ratio of -3.39 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same quarter in the previous year, the business posted ($0.76) EPS. Research analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.